Olema Pharmaceuticals, Inc.OLMANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +27.32% | +7.23% | +53.72% | +51.91% | +49.72% |
| Weighted Average Shares Diluted Growth | +27.32% | +7.23% | +53.72% | +51.91% | +49.72% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +215.01% | +189.16% | +234.47% | +332.46% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -21.39% | +62.84% | +55.35% | +50.07% | +53.13% |
| Book Value per Share Growth | -43.21% | +50.22% | +5.56% | +0.05% | +3.25% |
| Debt Growth | -35.23% | -40.88% | -48.03% | +142.35% | +163.57% |
| R&D Expense Growth | +70.80% | +24.84% | +2.48% | +50.82% | +20.24% |
| SG&A Expenses Growth | +13.01% | -1.65% | -4.65% | -10.38% | +34.84% |